Cargando…
The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
Patients with obstructive sleep apnea (OSA) have high rates of co-occurring type 2 diabetes, hypertension, obesity, stroke, congestive heart failure, and accelerated atherosclerotic cardiovascular diseases. These conditions frequently require multiple medications, raising the risk of polypharmacy, a...
Autores principales: | Sultana, Rizwana, Sissoho, Fatoumatta, Kaushik, Vinod P., Raji, Mukaila A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410036/ https://www.ncbi.nlm.nih.gov/pubmed/36013401 http://dx.doi.org/10.3390/life12081222 |
Ejemplares similares
-
Effects of glucagon-like peptide 1 receptor agonists on comorbidities
in older patients with diabetes mellitus
por: Onoviran, Olusola F., et al.
Publicado: (2019) -
Beneficial Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Asthma: A Literature Review
por: Kanwar, Meeta K, et al.
Publicado: (2022) -
Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012) -
Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021) -
Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach
por: Kalra, Sanjay
Publicado: (2014)